Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
September 12, 2024 07:00 ET
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 19, 2024 07:00 ET
|
Apogee Therapeutics, LLC
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in...
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
May 28, 2024 07:30 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
TRUGOLF RELEASES GROUNDBREAKING E6 APEX RANGE TRAINING SOFTWARE AND SIGNS JOE HALLETT, PGA COACH OF THE YEAR
April 08, 2024 09:00 ET
|
TruGolf Holdings, Inc.
SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc.(Nasdaq: TRUG) ("TruGolf”), among the leading sellers and distributors of golf simulator software and hardware, today...
Retrieve Medical Holdings, Inc. (RMHI) Announces Study Update Results Utilizing Retrieve Dx ™ Software
March 22, 2024 08:00 ET
|
Retrieve Medical, Inc.
RETRIEVE MEDICAL HOLDINGS, INC. (RMHI) ANNOUNCES STUDY UPDATE RESULTS UTILIZING RETRIEVE DxTM SOFTWARE
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
March 07, 2024 18:49 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024 06:10 ET
|
Apogee Therapeutics, LLC
Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to...
Retrieve Medical Holdings, Inc. Forges Partnership with Louisiana Health System Hospitals
February 26, 2024 09:00 ET
|
Retrieve Medical, Inc.
Retrieve Medical Holdings, Inc. Forges Partnership with Louisiana Health System Hospitals
Human Papillomavirus Vaccine Market is Poised to Reach USD 9.1 billion by 2031 | Transparency Market Research, Inc.
January 12, 2024 10:27 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global human papillomavirus vaccine market was projected to attain US$ 4 billion in...
Retrieve Medical Holdings, Inc. (RMHI) Announces Study Results Utilizing Retrieve Dx™ Software
October 24, 2023 11:16 ET
|
Retrieve Medical, Inc.
STUDY RESULTS UTILIZING RETRIEVE DX SOFTWARE